Lantheus (LNTH) investor relations material

Executive summary

• A definitive agreement was signed for the acquisition by Curium US Holdings LLC, with closing expected in the first half of 2027.

• The merger will create a global radiopharmaceutical leader, combining complementary strengths in nuclear medicine.

• Until closing, operations, supply, and service will remain unchanged, with no disruption expected for vendors or customers.

• The transaction is subject to customary closing conditions, including regulatory approvals and shareholder vote.

• Forward-looking statements highlight anticipated benefits, integration plans, and ongoing focus on radiodiagnostic business.

Voting matters and shareholder proposals

• Shareholders will be asked to vote on the proposed merger at a special meeting, with proxy materials to be provided in advance.

• The merger is contingent on shareholder approval and satisfaction of other conditions outlined in the merger agreement.

Board of directors and corporate governance

• Directors, executive officers, and employees of both companies may participate in proxy solicitation.

• Information on directors and executive officers is available in recent SEC filings, with updates to be included in the definitive proxy statement.